We agree with Bergua et al.1 on the possible superior efficacy of combination therapy treatment with rituximab and chemotherapy in CD20-positive multiple myeloma, with respect to rituximab alone, due to its synergism with many cytotoxic drugs. Nevertheless, the intention of our case report2 was to highlight a possible role of subsequent immunotherapy after debulking with chemotherapy to reduce the residual disease.
|Titolo:||Reply to “Rituximab activity in CD20-positive multiple myeloma”|
|Citazione:||Gozzetti, A., Fabbri, A., Lazzi, S., Bocchia, M., & Lauria, F. (2008). Reply to “Rituximab activity in CD20-positive multiple myeloma”. LEUKEMIA, 22, 1083-1084.|
|Appare nelle tipologie:||1.1 Articolo in rivista|
File in questo prodotto: